PL355596A1 - Female sexual disorder treating therapies and method of identifying compounds being useful in treating female sexual disorders - Google Patents

Female sexual disorder treating therapies and method of identifying compounds being useful in treating female sexual disorders

Info

Publication number
PL355596A1
PL355596A1 PL02355596A PL35559602A PL355596A1 PL 355596 A1 PL355596 A1 PL 355596A1 PL 02355596 A PL02355596 A PL 02355596A PL 35559602 A PL35559602 A PL 35559602A PL 355596 A1 PL355596 A1 PL 355596A1
Authority
PL
Poland
Prior art keywords
female sexual
treating
useful
therapies
identifying compounds
Prior art date
Application number
PL02355596A
Other languages
English (en)
Inventor
Philip Albert Carpino
John Richard Neville Hadcock
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL355596A1 publication Critical patent/PL355596A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyrrole Compounds (AREA)
PL02355596A 2001-08-21 2002-08-21 Female sexual disorder treating therapies and method of identifying compounds being useful in treating female sexual disorders PL355596A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31423001P 2001-08-21 2001-08-21

Publications (1)

Publication Number Publication Date
PL355596A1 true PL355596A1 (en) 2003-02-24

Family

ID=23219117

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02355596A PL355596A1 (en) 2001-08-21 2002-08-21 Female sexual disorder treating therapies and method of identifying compounds being useful in treating female sexual disorders

Country Status (10)

Country Link
US (1) US20030083228A1 (OSRAM)
EP (1) EP1285658A3 (OSRAM)
JP (1) JP2003119155A (OSRAM)
KR (1) KR20030017370A (OSRAM)
CN (1) CN1403157A (OSRAM)
CA (1) CA2398766A1 (OSRAM)
HU (1) HUP0202719A3 (OSRAM)
IL (1) IL151317A0 (OSRAM)
PL (1) PL355596A1 (OSRAM)
ZA (1) ZA200206612B (OSRAM)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997012623A1 (en) * 1995-10-06 1997-04-10 Arch Development Corporation Methods and compositions for viral enhancement of cell killing
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
WO2003013571A1 (en) * 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7550602B1 (en) * 2004-01-14 2009-06-23 Palatin Technologies, Inc. Small molecule compositions for sexual dysfunction
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
JP4879165B2 (ja) 2004-04-20 2012-02-22 トランス テック ファーマ，インコーポレイテッド メラノコルチン受容体の調節因子としての置換チアゾール及びピリミジン誘導体
AU2005235422B2 (en) * 2004-04-22 2011-08-11 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders II
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
SI2275098T1 (sl) * 2004-05-04 2012-12-31 Hormos Medical Ltd. Nove oralne formulacije ospemifena
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
US20060034978A1 (en) * 2004-08-16 2006-02-16 Grain Processing Corporation Aerosol compositions, devices and methods
CA2576812A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008538741A (ja) * 2005-03-04 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 鬱病の治療用及び／又は予防用の医薬組成物
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CA2654152A1 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
RU2301067C1 (ru) * 2006-06-19 2007-06-20 Сергей Павлович Соловьев Средство и способ для повышения половой активности человека
EP2037927B1 (en) * 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
WO2008019996A2 (en) 2006-08-14 2008-02-21 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
JP5220746B2 (ja) 2006-08-25 2013-06-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 制御放出システム及びその製造方法
US8722682B2 (en) 2006-12-20 2014-05-13 Sprout Pharmaceuticals, Inc. Sulfated benzimidazolone derivatives having mixed serotonin receptor affinity
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CA2731442A1 (en) 2008-08-29 2010-03-04 Transtech Pharma, Inc. Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
EP2381947A4 (en) 2008-12-23 2012-08-22 Quest Diagnostics Invest Inc MASS SPECTROMETRY ASSAY FOR STROGENIC COMPOUNDS
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CA2933921A1 (en) * 2016-06-17 2017-12-17 S1 Biopharma, Inc. Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment
CN108358999A (zh) * 2018-01-17 2018-08-03 南京师范大学 一种雌激素受体靶向肽及其制备和应用
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
JP2002517444A (ja) * 1998-06-11 2002-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としてのスピロピペリジン誘導体
WO2001005401A1 (en) * 1999-07-16 2001-01-25 Trega Biosciences, Inc. Melanocortin receptor-3 ligands to treat sexual dysfunction
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds

Also Published As

Publication number Publication date
US20030083228A1 (en) 2003-05-01
HU0202719D0 (OSRAM) 2002-10-28
ZA200206612B (en) 2004-02-19
IL151317A0 (en) 2003-04-10
KR20030017370A (ko) 2003-03-03
CN1403157A (zh) 2003-03-19
EP1285658A3 (en) 2004-01-28
CA2398766A1 (en) 2003-02-21
HUP0202719A2 (hu) 2003-04-28
HUP0202719A3 (en) 2006-01-30
JP2003119155A (ja) 2003-04-23
EP1285658A2 (en) 2003-02-26

Similar Documents

Publication Publication Date Title
PL355596A1 (en) Female sexual disorder treating therapies and method of identifying compounds being useful in treating female sexual disorders
EG23117A (en) Method and apparatus for stimulation of multiple formation inyervals
ZA200308316B (en) Fusion molecules and methods for treatment of immune diseases
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
AU2003286611A8 (en) Cytomodulating peptides and methods for treating neurological disorders
IL160278A0 (en) System and method for face and body treatment
IL174918A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL148034A0 (en) Methods of treating nuclear factor-kappa b mediated diseases and disorders
AU2001237911A1 (en) System and method for determining stimulation parameters for the treatment of epileptic seizures
IL149070A0 (en) Apparatus and method for targeted uv phototherapy of skin disorders
AU2002351378A8 (en) Method and apparatus for treatment of amblyopia
HUP0501017A3 (en) Methods and compositions for treatment of central nervous system disorders
IL159313A0 (en) Methods for treatment of cognitive and menopausal disorders with d-threo-methylphenidate
EP1567198A4 (en) MATERIALS AND METHOD FOR THE TREATMENT OF EYE DISEASES
IL165216A0 (en) Methods of treating gastrointestinal and genitouririnary pain disorders using vinlafaxin and derivatives
AU5754701A (en) Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
AU2003272728A8 (en) Methods and compositions for treatment of neurological disorder
EP1445353A4 (en) METHOD AND DEVICE FOR SURFACE TREATMENT OF TREATED OBJECT
EP1581095A4 (en) THERAPEUTIC METHODS FOR REDUCING FAT DEPOSIT AND TREATING THE DISEASES THEREOF
AU2002362115A8 (en) Composition and methods for treatment of neurological disorders
AU2002335657A8 (en) Neural regeneration peptide and methods for their use in treatment of brain damage
EP1400212A4 (en) APPARATUS AND METHOD FOR TREATING JOINT DISEASES
AU2002304931A1 (en) Methods for treating disorders of the nervous and reproductive systems
PL363354A1 (en) Method for preventing and treating visceral pain and gastrointestinal disorders
AU2003301346A8 (en) Method of treating neurological diseases and disorders

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)